Loading...
Loading...
PCVX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 162.2M |
| Operating I/L | -162.2M |
| Other Income/Expense | 25.1M |
| Interest Income | 36.5M |
| Pretax | -137.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -137.1M |
Vaxcyte, Inc. is a clinical-stage biotechnology company specializing in the development of novel protein vaccines to prevent and treat bacterial infectious diseases. The company's lead vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials for the treatment of invasive pneumococcal disease and pneumonia. Additionally, Vaxcyte is developing VAX-XP to address emerging strains and antibiotic resistance, VAX-A1 for Group A Strep, and VAX-PG targeting the keystone pathogen responsible for periodontitis.
